William Blair & Company’s Madrigal Pharmaceuticals MDGL Stock Holding History

William Blair & Company’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$542K	Buy	1,009 +8	+0.8%	+$4.1K	﹤0.01%	1201
2026 Q1	$524K	Buy	1,001 +1	+0.1%	+$478	﹤0.01%	1132
2025 Q4	$582K	Hold	1,000	–	–	﹤0.01%	1087
2025 Q3	$459K	Hold	1,000	–	–	﹤0.01%	1146
2025 Q2	$303K	Sell	1,000 -3	-0.3%	-$894	﹤0.01%	1261
2025 Q1	$332K	Buy	+1,003	New	+$330K	﹤0.01%	1219
2018 Q4	–	Sell	-2,250	Closed	-$482K	–	1740
2018 Q3	$482K	Sell	2,250 -3,470	-61%	-$871K	﹤0.01%	965
2018 Q2	$1.6M	Buy	5,720 +2,641	+86%	+$464K	0.01%	601
2018 Q1	$360K	Buy	+3,079	New	+$380K	﹤0.01%	1023

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

William Blair & Company's MDGL Position: Q2 2026 in Review

William Blair & Company increased its Madrigal Pharmaceuticals (MDGL) stake by 0.8% in Q2 2026, buying an estimated $4.1K and bringing the position to 1,009 shares worth $542K. The position accounts for ﹤0.01% of the portfolio, ranked #1201.

William Blair & Company first reported a position in MDGL in Q1 2018 and has held it in 9 quarters since. The position peaked at $1.6M in Q2 2018. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

William Blair & Company held 1,009 shares of Madrigal Pharmaceuticals worth $542K as of Q2 2026.
William Blair & Company bought 8 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $4.1K.
Madrigal Pharmaceuticals made up ﹤0.01% of William Blair & Company's portfolio in Q2 2026, its #1201 holding.
William Blair & Company first reported a position in Madrigal Pharmaceuticals in Q1 2018 and has held it in 9 quarters since.
William Blair & Company's Madrigal Pharmaceuticals position peaked at $1.6M in Q2 2018.
414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on William Blair & Company's 13F filing for Q2 2026, filed 11 Aug 2026.